(TSX-V:CPI),(OTC US:NBRFF),(OTCQB:NBRFF), TORONTO, July 07, 2025 (GLOBE NEWSWIRE) — Carlton Precious Inc. (TSX-V: CPI | OTCQB: NBRFF) (“Carlton” or the “Company“) is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held July 3, 2025. A total of 28,620,194 common shares of the Company were represented at the Meeting, […]
(TSX:VHI),(OTC US:VHIBF),(Other OTC:VHIBF), TORONTO, July 07, 2025 (GLOBE NEWSWIRE) — Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) is pleased to announce that it has acquired (the “Acquisition”) Novari Health Inc. (“Novari”), a leading healthcare software provider of patient flow solutions based in Canada. Transaction Details VitalHub has acquired Novari for total up-front consideration of
(NASDAQ:BYSI), In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated an overall response rate (ORR) of 23% and a disease control rate (DCR) of 54% in non-irradiated lesions. Biomarker analysis linked Plinabulin's mechanism to GEF-H1-dependent dendritic cell maturation, offering the potential to pre-select patients at baseline
(NASDAQ:TNXP), Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox TNX-801 confers durable protection after a single dose TNX-801 is well tolerated in immunocompromised animals, without evidence of spreading to blood or tissues even at high doses CHATHAM, N.J., July 07, 2025 (GLOBE NEWSWIRE) — Tonix
(NasdaqGM:LXEO), Breakthrough Therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures LX2006 also selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, created to facilitate CMC registrational readiness and support faster patient access NEW YORK, July 07, 2025 (GLOBE
(NasdaqGM:AXSM), NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will host its Frontiers in Brain Health R&D Day on July 21, 2025, starting at 11:00 a.m. Eastern Time in New
(NASDAQ:GNLX), WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July 1, 2025. “We are delighted to welcome Eric to the executive team,” said Thomas
(CNSX:LCR.CN),(OTC US:LANRF),(Other OTC:LANRF),(Boerse Frankfurt – Freiverkehr:6UF0), VANCOUVER, British Columbia, July 07, 2025 (GLOBE NEWSWIRE) — Lancaster Resources Inc. (CSE:LCR) (OTC Pink:LANRF) (FRA:6UF0) (“Lancaster“, the “Company“) is pleased to announce the completion of its acquisition of 100% of the Lake Cargelligo Gold Project, a district-scale exploration property in the famed Cobar mining district of New South
HIGH RIVER, Alberta, July 07, 2025 (GLOBE NEWSWIRE) — Western Financial Group is proud to announce it has been named a recipient of the 2025 Canadian Business Excellence Award for Private Businesses, presented by Excellence Canada. This national recognition celebrates organizations that demonstrate outstanding customer experience, employee engagement, and innovation. “This award is a reflection
(NasdaqGM:NRIX), SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to bexobrutideg (NX-5948) for the treatment of lymphoplasmacytic lymphoma. Bexobrutideg is